Supernus Pharmaceuticals, Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 32.4%, EPS fell 352.5% and free cash flow fell 109.3%, each against the same quarter a year earlier.
Follow SUPN
Supernus Pharmaceuticals, Inc. (SUPN) EV/Sales
As of 16 October 2026, Supernus Pharmaceuticals, Inc. (SUPN) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 1.9× (March 2020) to 9.6× (September 2017); the current reading is higher than 18% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.1× | 35.77% |
| FY2024 | 3.0× | 6.67% |
| FY2023 | 2.9× | (19.16%) |
| FY2022 | 3.5× | 28.59% |
| FY2021 | 2.7× | 12.56% |
| FY2020 | 2.4× | (23.09%) |
| FY2019 | 3.2× | (23.64%) |
| FY2018 | 4.2× | (34.35%) |
| FY2017 | 6.3× | 13.70% |
| FY2016 | 5.6× | 40.90% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.4× | (14.57%) |
| Mar 2026 | 4.0× | (4.38%) |
| Dec 2025 | 4.1× | (2.74%) |
| Sep 2025 | 4.3× | 64.36% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| PRGO Perrigo Company plc compare | 1.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. | 2.8× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| LQDA Liquidia Corporation compare | 6.5× |
| ALVO Alvotech compare | 9.0× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)